These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 10926284)
1. Erythropoietin therapy for premature infants: cost without benefit? Zipursky A Pediatr Res; 2000 Aug; 48(2):136. PubMed ID: 10926284 [No Abstract] [Full Text] [Related]
2. Financial impact of the introduction of erythropoietin in the treatment of anemia of premature infants in Israel. Dollberg S; Mimouni FB Isr Med Assoc J; 1999 Oct; 1(2):86-8. PubMed ID: 10731302 [TBL] [Abstract][Full Text] [Related]
3. Is the use of recombinant human erythropoietin in anaemia of prematurity cost-effective? Meyer MP; Haworth C; McNeill L S Afr Med J; 1996 Mar; 86(3):251-3. PubMed ID: 8658295 [TBL] [Abstract][Full Text] [Related]
4. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. Maier RF; Obladen M; Scigalla P; Linderkamp O; Duc G; Hieronimi G; Halliday HL; Versmold HT; Moriette G; Jorch G N Engl J Med; 1994 Apr; 330(17):1173-8. PubMed ID: 8139627 [TBL] [Abstract][Full Text] [Related]
6. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin. McNamee P; van Doorslaer E; Segaar R Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425 [TBL] [Abstract][Full Text] [Related]
7. Avoiding transfusion in head and neck surgery: feasibility study of erythropoietin. Sturgis EM; Gianoli GJ; Miller RH; Fisher JW Laryngoscope; 2000 Jan; 110(1):51-7. PubMed ID: 10646716 [TBL] [Abstract][Full Text] [Related]
8. Symposium: options in transfusion therapy. Nelson CL; Keating EM; Murray DG; Schurman DJ Contemp Orthop; 1994 Oct; 29(4):283-94, 298-305. PubMed ID: 10150251 [No Abstract] [Full Text] [Related]
9. Anemia of prematurity: the prospects for avoiding blood transfusions by treatment with recombinant human erythropoietin. Dallman PR Adv Pediatr; 1993; 40():385-403. PubMed ID: 8249712 [No Abstract] [Full Text] [Related]
10. Avoiding a blood transfusion: How much is it worth? Corwin HL; Hebert P Crit Care Med; 2005 Mar; 33(3):672-4. PubMed ID: 15753765 [No Abstract] [Full Text] [Related]
11. Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Finkelstein SN; Huber SL; Greenberg PE Ann Pharmacother; 1997 Sep; 31(9):1094-5. PubMed ID: 9296258 [No Abstract] [Full Text] [Related]
12. Erythropoietin to prevent transfusions in premature infants. Alfaleh K; Thabane L J Perinatol; 2005 Aug; 25(8):560. PubMed ID: 16047037 [No Abstract] [Full Text] [Related]
13. Recombinant erythropoietic growth factors as an alternative to erythrocyte transfusion for patients with "anemia of prematurity". Christensen RD Pediatrics; 1989 May; 83(5):793-6. PubMed ID: 2717299 [No Abstract] [Full Text] [Related]
14. Early treatment of premature infants with recombinant human erythropoietin. Messer J; Haddad J; Donato L; Astruc D; Matis J Pediatrics; 1993 Oct; 92(4):519-23. PubMed ID: 8414820 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children. Allen UD; Kirby MA; Goeree R Pediatr AIDS HIV Infect; 1997 Feb; 8(1):4-11. PubMed ID: 11361510 [TBL] [Abstract][Full Text] [Related]
16. [Erythropoietin treatment: concept and controversy]. Sans Mateu T Sangre (Barc); 1998 Aug; 43(4):327-30. PubMed ID: 9790000 [No Abstract] [Full Text] [Related]